Matches in SemOpenAlex for { <https://semopenalex.org/work/W2241228657> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2241228657 endingPage "7172" @default.
- W2241228657 startingPage "7172" @default.
- W2241228657 abstract "7172 Background: The combination of pemetrexed (P) and carboplatin (C) was found to be active and well tolerated in MPM in a phase I trial (Hughes, JCO 2002). Aim of our study was to explore this combination in a Phase II setting in patients affected by MPM. Methods: From 11/02 to 10/04, 87 chemo-naive patients (pts) with unresectable MPM were enrolled from 8 Italian institutions. Therapy consisted of P 500 mg/m2 given as a 10-minute intravenous infusion, followed by C AUC 5 administered as a 30-minute intravenous infusion. Treatment was repeated every 21 days for a maximum of 6 cycles or until progression or unacceptable toxicity. All pts received folic acid and vitamin B12 supplementation, and steroid prophylaxis. Results: All pts had unresectable disease; 10 had relapses after radical surgery. Their characteristics were: M/F 65/22; PS 0/1/2 27/52/8; median age 65 years (range:38–79). Histology was epithelial in 69 (79%), sarcomatoid in 5 (6%), mixed in 8 (9%), unclassified in 5 (6%). Seventy-eight pts were evaluable for response, toxicity and survival; the remaining 9 are still on treatment. Response rate was 20% (95% CI 12–31%), with 1 CR and 15 PR; SD was observed in 34 pts (44%, 95% CI 32–55%), PD in 28 (36%, 95% CI 25–48%). A total of 368 cycles were delivered. Grade (G) 3–4 hematological toxicity consisted of neutropenia in 14 pts (18%, febrile neutropenia in 1 case only), anemia in 10 (13%), thrombocytopenia in 5 (6%). Non-hematological toxicity was generally mild: G 3–4 diarrhea in 3 pts (4%), G 1–2 conjunctivitis in 12 (15%),G 1–2 asthenia in 27 (35%). With a median follow-up of 5.2 months (range 0.8–21.9), 25 pts died and 53 are still alive. Median time to progression was 6 months (range 0.3–11.3). Conclusions: This Phase II trial confirms the encouraging activity of the combination of P and C in MPM. The excellent toxicity profile of this regimen strongly supports its use as front-line therapy as well as in the neoadjuvant setting of MPM. No significant financial relationships to disclose." @default.
- W2241228657 created "2016-06-24" @default.
- W2241228657 creator A5026639715 @default.
- W2241228657 creator A5032477448 @default.
- W2241228657 creator A5051919018 @default.
- W2241228657 creator A5055283283 @default.
- W2241228657 creator A5058647288 @default.
- W2241228657 creator A5062532607 @default.
- W2241228657 creator A5071606172 @default.
- W2241228657 creator A5078987153 @default.
- W2241228657 creator A5087455044 @default.
- W2241228657 creator A5089891961 @default.
- W2241228657 date "2005-06-01" @default.
- W2241228657 modified "2023-10-16" @default.
- W2241228657 title "A phase II study of pemetrexed and carboplatin as front-line chemotherapy in patients with malignant pleural mesothelioma (MPM)" @default.
- W2241228657 doi "https://doi.org/10.1200/jco.2005.23.16_suppl.7172" @default.
- W2241228657 hasPublicationYear "2005" @default.
- W2241228657 type Work @default.
- W2241228657 sameAs 2241228657 @default.
- W2241228657 citedByCount "8" @default.
- W2241228657 crossrefType "journal-article" @default.
- W2241228657 hasAuthorship W2241228657A5026639715 @default.
- W2241228657 hasAuthorship W2241228657A5032477448 @default.
- W2241228657 hasAuthorship W2241228657A5051919018 @default.
- W2241228657 hasAuthorship W2241228657A5055283283 @default.
- W2241228657 hasAuthorship W2241228657A5058647288 @default.
- W2241228657 hasAuthorship W2241228657A5062532607 @default.
- W2241228657 hasAuthorship W2241228657A5071606172 @default.
- W2241228657 hasAuthorship W2241228657A5078987153 @default.
- W2241228657 hasAuthorship W2241228657A5087455044 @default.
- W2241228657 hasAuthorship W2241228657A5089891961 @default.
- W2241228657 hasConcept C126322002 @default.
- W2241228657 hasConcept C141071460 @default.
- W2241228657 hasConcept C142724271 @default.
- W2241228657 hasConcept C2776694085 @default.
- W2241228657 hasConcept C2777063308 @default.
- W2241228657 hasConcept C2777240266 @default.
- W2241228657 hasConcept C2777407522 @default.
- W2241228657 hasConcept C2778239845 @default.
- W2241228657 hasConcept C2778248108 @default.
- W2241228657 hasConcept C2778850193 @default.
- W2241228657 hasConcept C2781451048 @default.
- W2241228657 hasConcept C29730261 @default.
- W2241228657 hasConcept C31760486 @default.
- W2241228657 hasConcept C71924100 @default.
- W2241228657 hasConcept C90924648 @default.
- W2241228657 hasConceptScore W2241228657C126322002 @default.
- W2241228657 hasConceptScore W2241228657C141071460 @default.
- W2241228657 hasConceptScore W2241228657C142724271 @default.
- W2241228657 hasConceptScore W2241228657C2776694085 @default.
- W2241228657 hasConceptScore W2241228657C2777063308 @default.
- W2241228657 hasConceptScore W2241228657C2777240266 @default.
- W2241228657 hasConceptScore W2241228657C2777407522 @default.
- W2241228657 hasConceptScore W2241228657C2778239845 @default.
- W2241228657 hasConceptScore W2241228657C2778248108 @default.
- W2241228657 hasConceptScore W2241228657C2778850193 @default.
- W2241228657 hasConceptScore W2241228657C2781451048 @default.
- W2241228657 hasConceptScore W2241228657C29730261 @default.
- W2241228657 hasConceptScore W2241228657C31760486 @default.
- W2241228657 hasConceptScore W2241228657C71924100 @default.
- W2241228657 hasConceptScore W2241228657C90924648 @default.
- W2241228657 hasIssue "16_suppl" @default.
- W2241228657 hasLocation W22412286571 @default.
- W2241228657 hasOpenAccess W2241228657 @default.
- W2241228657 hasPrimaryLocation W22412286571 @default.
- W2241228657 hasRelatedWork W1966056387 @default.
- W2241228657 hasRelatedWork W1980050012 @default.
- W2241228657 hasRelatedWork W1991613108 @default.
- W2241228657 hasRelatedWork W2037915643 @default.
- W2241228657 hasRelatedWork W2073646991 @default.
- W2241228657 hasRelatedWork W2134707435 @default.
- W2241228657 hasRelatedWork W2162555812 @default.
- W2241228657 hasRelatedWork W2397387063 @default.
- W2241228657 hasRelatedWork W2605313253 @default.
- W2241228657 hasRelatedWork W2606438018 @default.
- W2241228657 hasVolume "23" @default.
- W2241228657 isParatext "false" @default.
- W2241228657 isRetracted "false" @default.
- W2241228657 magId "2241228657" @default.
- W2241228657 workType "article" @default.